tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

GANX Stock Latest News

Gain initiated with Buy on Parkison’s potential at Roth MKM
The FlyGain initiated with Buy on Parkison’s potential at Roth MKM
17d ago
GANX
Gain Therapeutics initiated with a Buy at Roth MKM
PremiumThe Fly
Gain Therapeutics initiated with a Buy at Roth MKM
17d ago
GANX
Gain Therapeutics Advances Parkinson’s Therapy Development
PremiumCompany Announcements
Gain Therapeutics Advances Parkinson’s Therapy Development
1M ago
GANX
Closing Bell Movers: Applied Materials down 6% after earnings, guidance
PremiumThe Fly
Closing Bell Movers: Applied Materials down 6% after earnings, guidance
1M ago
DPZ
INO
Gain Therapeutics reports Q3 EPS (17c), consensus (21c)
PremiumThe Fly
Gain Therapeutics reports Q3 EPS (17c), consensus (21c)
1M ago
GANX
Is GANX a Buy, Before Earnings?
PremiumPre-EarningsIs GANX a Buy, Before Earnings?
2M ago
GANX
Gain Therapeutics presents data at 36th ENA symposium
Premium
The Fly
Gain Therapeutics presents data at 36th ENA symposium
2M ago
GANX
Gain Therapeutics to present at MJFF’s Annual Parkinson’s Disease Conference
Premium
The Fly
Gain Therapeutics to present at MJFF’s Annual Parkinson’s Disease Conference
2M ago
GANX
Gain Therapeutics Excels in Neurodegenerative Drug Trials
PremiumCompany Announcements
Gain Therapeutics Excels in Neurodegenerative Drug Trials
3M ago
8K
GANX
Gain Therapeutics presents preclinical data on GT-02287
PremiumThe Fly
Gain Therapeutics presents preclinical data on GT-02287
3M ago
GANX
Gain Therapeutics presents Phase 1 GT-02287 data
PremiumThe Fly
Gain Therapeutics presents Phase 1 GT-02287 data
3M ago
GANX
Gain Therapeutics to present preclinical data on GT-02287 at Neuroscience 2024
PremiumThe Fly
Gain Therapeutics to present preclinical data on GT-02287 at Neuroscience 2024
3M ago
GANX
Gain Therapeutics announces reuslts from Phase 1 study of GT-02287
PremiumThe FlyGain Therapeutics announces reuslts from Phase 1 study of GT-02287
4M ago
GANX
Gain Therapeutics assumed with an Outperform at Oppenheimer
Premium
The Fly
Gain Therapeutics assumed with an Outperform at Oppenheimer
4M ago
GANX
Gain Therapeutics reports Q2 EPS (42c), consensus (20c)
Premium
The Fly
Gain Therapeutics reports Q2 EPS (42c), consensus (20c)
5M ago
GANX
Gain Therapeutics Advances Parkinson’s Treatment in Phase 1
PremiumCompany Announcements
Gain Therapeutics Advances Parkinson’s Treatment in Phase 1
6M ago
8K
GANX
Gain Therapeutics completes dosing in MAD Phase 1 study of GT-02287
PremiumThe Fly
Gain Therapeutics completes dosing in MAD Phase 1 study of GT-02287
6M ago
GANX
Gain Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
PremiumThe Fly
Gain Therapeutics price target lowered to $8 from $9 at H.C. Wainwright
6M ago
GANX
Gain Therapeutics Leadership Changes and Executive Compensation
PremiumCompany Announcements
Gain Therapeutics Leadership Changes and Executive Compensation
6M ago
8K
GANX
Gain Therapeutics CEO Matthias Alder departs, Gene Mack named interim CEO
PremiumThe FlyGain Therapeutics CEO Matthias Alder departs, Gene Mack named interim CEO
6M ago
GANX
Gain Therapeutics announces presentation of poster at FENS forum 2024
Premium
The Fly
Gain Therapeutics announces presentation of poster at FENS forum 2024
6M ago
GANX
Gain Therapeutics Launches Public Offering and Warrants Deal
Premium
Company Announcements
Gain Therapeutics Launches Public Offering and Warrants Deal
6M ago
8K
GANX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >